ABCB4 and neoplasm: Moreover, treating aged Mdr2-deficient mice (which already had advanced liver fibrosis and HCC) with the Hh pathway inhibitor significantly reduced liver fibrosis and tumor burden, demonstrating for the first time that inhibiting Hh signaling has clinically-relevant, therapeutic value for both liver fibrosis and HCC.